Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Decreases By 28.7%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 50,200 shares, a decline of 28.7% from the February 29th total of 70,400 shares. Based on an average daily trading volume, of 93,300 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.5% of the company’s stock are sold short.

Aptose Biosciences Stock Up 10.7 %

NASDAQ:APTO opened at $1.66 on Friday. Aptose Biosciences has a 52 week low of $1.36 and a 52 week high of $9.90. The business’s 50 day moving average is $1.82 and its two-hundred day moving average is $2.35.

Hedge Funds Weigh In On Aptose Biosciences

Several large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its holdings in shares of Aptose Biosciences by 256.6% during the fourth quarter. Citadel Advisors LLC now owns 61,875 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 44,522 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Aptose Biosciences during the fourth quarter worth about $32,000. Annandale Capital LLC lifted its holdings in Aptose Biosciences by 40.0% in the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 21,334 shares during the last quarter. Sigma Planning Corp acquired a new position in Aptose Biosciences in the third quarter valued at approximately $408,000. Finally, DRW Securities LLC bought a new position in shares of Aptose Biosciences during the fourth quarter valued at approximately $5,158,000. 26.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on APTO shares. StockNews.com upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Aptose Biosciences in a research note on Wednesday. Finally, Piper Sandler dropped their price target on shares of Aptose Biosciences from $12.00 to $5.00 and set an “overweight” rating for the company in a research note on Thursday, February 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.80.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.